← Leaderboards
Wen Xie
University Of Pittsburgh At Pittsburgh
$22,052,503
Attributed
$22,052,503
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,052,503 · 12
By mechanism
R01$15,584,003 · 10
R35$6,051,875 · 1
R21$416,625 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Enzymes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Randall J Bateman · Washington University$83,824,814
- Stuart L Schreiber · Harvard University (Medical School)$49,424,554
- Jay D Keasling · University Of California-Berkeley$47,558,861
- David Heimbrook · Leidos Biomedical Research, Inc.$47,513,682
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
EnzymesRegulationHepaticXenobioticsBaseLiverMolecularGeneticReceptorGenesMediatingTransgenic OrganismsNuclear ReceptorsPlayTransgenic MiceHomeostasisKnock-OutPromotor (Genetics)HepatocyteResponsePharmaceutical PreparationsAgonistTransgenesInflammation
Grant awards (57)
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity$814,679
R35 · FY2025 · ES · contact PI
Cellular and Metabolic Basis of the Role of CYP1B1 in Liver Fibrosis$375,099
R01 · FY2025 · DK · contact PI
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity$827,199
R35 · FY2024 · ES · contact PI
Cellular and Metabolic Basis of the Role of CYP1B1 in Liver Fibrosis$400,107
R01 · FY2024 · DK · contact PI
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity$855,738
R35 · FY2023 · ES · contact PI
Cellular and Metabolic Basis of the Role of CYP1B1 in Liver Fibrosis$431,527
R01 · FY2023 · DK · contact PI
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity$864,263
R35 · FY2022 · ES · contact PI
PXR-Mediated Xenobiotic Response in the Pathogenesis Hemorrhagic Shock$352,125
R01 · FY2022 · DK · contact PI
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity$875,639
R35 · FY2021 · ES · contact PI
PXR-Mediated Xenobiotic Response in the Pathog enesis Hemorrhagic Shock$352,125
R01 · FY2021 · DK · contact PI
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity$888,526
R35 · FY2020 · ES · contact PI
PXR-Mediated Xenobiotic Response in the Pathog enesis Hemorrhagic Shock$352,125
R01 · FY2020 · DK · contact PI
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity$925,831
R35 · FY2019 · ES · contact PI
PXR-Mediated Xenobiotic Response in the Pathogenesis Hemorrhagic Shock$352,125
R01 · FY2019 · DK · contact PI
The AHR-FGF221 Axis in Hepatic Steatosis and Metobolic Syndrome$352,125
R01 · FY2019 · DK · contact PI
The AHR-FGF221 Axis in Hepatic Steatosis and Metobolic Syndrome$351,563
R01 · FY2018 · DK · contact PI
A Novel Regulation of the Phase II Enzyme Estrogen Sulfotransferase$346,500
R01 · FY2018 · ES · contact PI
The AHR-FGF221 Axis in Hepatic Steatosis and Metobolic Syndrome$349,031
R01 · FY2017 · DK · contact PI
A Novel Regulation of the Phase II Enzyme Estrogen Sulfotransferase$346,500
R01 · FY2017 · ES · contact PI
The hepatic function of cholesterol sulfotransferase 2B1b (SULT2B1b)in energy met$334,950
R01 · FY2017 · DK · contact PI
The Perinatal Pharmacology of the Nuclear Receptor$319,550
R01 · FY2017 · HD · contact PI
A Novel Regulation of the Phase II Enzyme Estrogen Sulfotransferase$346,500
R01 · FY2016 · ES · contact PI
The AHR-FGF221 Axis in Hepatic Steatosis and Metobolic Syndrome$346,500
R01 · FY2016 · DK · contact PI
The hepatic function of cholesterol sulfotransferase 2B1b (SULT2B1b)in energy met$334,950
R01 · FY2016 · DK · contact PI
The Perinatal Pharmacology of the Nuclear Receptor$316,354
R01 · FY2016 · HD · contact PI
A Novel Regulation of the Phase II Enzyme Estrogen Sulfotransferase$346,500
R01 · FY2015 · ES · contact PI
The hepatic function of cholesterol sulfotransferase 2B1b (SULT2B1b)in energy met$334,950
R01 · FY2015 · DK · contact PI
The Perinatal Pharmacology of the Nuclear Receptor$311,560
R01 · FY2015 · HD · contact PI
A Novel Regulation of the Phase II Enzyme Estrogen Sulfotransferase$346,500
R01 · FY2014 · ES · contact PI
The hepatic function of cholesterol sulfotransferase 2B1b (SULT2B1b)in energy met$334,950
R01 · FY2014 · DK · contact PI
A Novel Role of the Aryl Hydrocarbon Receptor in Hepatic Steatosis$311,219
R01 · FY2014 · DK · contact PI
The Perinatal Pharmacology of the Nuclear Receptor$307,577
R01 · FY2014 · HD · contact PI
The Perinatal Pharmacology of the Nuclear Receptor$316,438
R01 · FY2013 · HD · contact PI
A Novel Role of the Aryl Hydrocarbon Receptor in Hepatic Steatosis$300,326
R01 · FY2013 · DK · contact PI
A Novel Role of the Aryl Hydrocarbon Receptor in Hepatic Steatosis$311,219
R01 · FY2012 · DK · contact PI
The Regulation of Human Hydroxysteroid Sulfotransferase by Nuclear Receptor ROR$227,250
R21 · FY2012 · ES · contact PI
Regulation of Sulfotransferases by LXR and its Implication in Pathophysiology$340,197
R01 · FY2011 · ES · contact PI
A Novel Role of the Aryl Hydrocarbon Receptor in Hepatic Steatosis$311,219
R01 · FY2011 · DK · contact PI
The Regulation of Human Hydroxysteroid Sulfotransferase by Nuclear Receptor ROR$189,375
R21 · FY2011 · ES · contact PI
The Hepatoprotective Role of the Orphan Nuclear Receptor LXR$453,897
R01 · FY2010 · DK · contact PI
A Novel Role of the Aryl Hydrocarbon Receptor in Hepatic Steatosis$378,750
R01 · FY2010 · DK · contact PI
Regulation of Sulfotransferases by LXR and its Implication in Pathophysiology$303,913
R01 · FY2010 · ES · contact PI
Regulation of Sulfotransferases by LXR and its Implication in Pathophysiology$28,721
R01 · FY2010 · ES · contact PI
The Hepatoprotective Role of the Orphan Nuclear Receptor LXR$446,369
R01 · FY2009 · DK · contact PI
Regulation of Sulfotransferases by LXR and its Implication in Pathophysiology$307,578
R01 · FY2009 · ES · contact PI
Regulation of Sulfotransferases by LXR and its Implication in Pathophysiology$308,157
R01 · FY2008 · ES · contact PI
PXR Controlled Bile Acid Detoxification in Colon Cancer$264,679
R01 · FY2008 · CA · contact PI
Regulation of Sulfotransferases by LXR and its Implication in Pathophysiology$315,019
R01 · FY2007 · ES · contact PI
Phase II UDP-glucuronosyltransferases by PXR$277,682
R01 · FY2007 · ES · contact PI
PXR Controlled Bile Acid Detoxification in Colon Cancer$264,806
R01 · FY2007 · CA · contact PI
Phase II UDP-glucuronosyltransferases by PXR$286,784
R01 · FY2006 · ES · contact PI
PXR Control Bile Acid Detoxification in Colon Cancer$272,841
R01 · FY2006 · CA · contact PI
Phase II UDP-glucuronosyltransferases by PXR$294,488
R01 · FY2005 · ES
PXR Control Bile Acid Detoxification in Colon Cancer$279,533
R01 · FY2005 · CA
Phase II UDP-glucuronosyltransferases by PXR$295,267
R01 · FY2004 · ES
PXR Controlled Bile Acid Detoxification in Colon Cancer$279,848
R01 · FY2004 · CA
Phase II UDP-glucuronosyltransferases by PXR$293,260
R01 · FY2003 · ES